{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117891","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.766254+00:00","generated_at":"2026-06-21T19:55:13.532192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Immunome reports Q3 net loss of $8.5M; cash $27.1M; COVID antibody trial on track","bullets":["Net loss for Q3 2022 was $8.5 million; no revenue from product sales.","R&D expenses $5.2M, G&A $3.3M; cash and equivalents $27.1M as of Sept 30.","IMM-BCP-01 Phase 1b enrollment expected by end of 2022; topline data early 2023.","Oncology pipeline advancing; IND for IMM-ONC-01 planned by mid-2023.","Preclinical data on anti-EPN1 antibody IMM20059 at SITC showed combo effect with atezolizumab."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117891","json":"https://secwatch.observer/filing/0001104659-22-117891.json","markdown":"https://secwatch.observer/filing/0001104659-22-117891.md","text":"https://secwatch.observer/filing/0001104659-22-117891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/0001104659-22-117891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/tm2230173d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:55:13.532192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e80a10c65841b0b0822087a669f7edd5ee6af77a","claim":"Immunome Inc. reported third quarter ended September 30, 2022 results: net income $8.5 million.","evidence_excerpt":"Net loss: Net loss for the three months ended 2022 was $8.5 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465922117891/0001104659-22-117891-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}